-- PYC Therapeutics（澳洲證券交易所代碼：PYC）週一向澳洲證券交易所提交的文件顯示，其用於治療致盲性眼疾－11型視網膜色素變性（Retinitis Pigmentosa type 11）的候選藥物VP-001已獲得歐洲藥品管理局（EMA）授予的孤兒藥資格認定。 此認定帶來的益處包括：獲得歐洲監管機構的科學建議和其他支持；降低藥物審查的監管費用；以及獲準後在歐洲市場享有10年的獨佔權。 PYC Therapeutics表示，VP-001先前已獲得美國食品藥物管理局（FDA）授予的孤兒藥資格認定和快速通道資格。
Related Articles
US Markets
Organon Agrees to Be Acquired by Sun Pharmaceutical in $11.75 Billion Deal
Organon (OGN) shares spiked early Monday after the healthcare company agreed to be acquired by Indian pharmaceutical firm Sun Pharmaceutical Industries in an all-cash deal with an enterprise value of about $11.75 billion.Shareholders of Organon will receive $14 a share in cash under the terms of the transaction, the companies said in a joint statement on Sunday. Organon's stock jumped 15% in the most recent premarket activity."Following a comprehensive review of strategic alternatives, our board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders," Organon Chief Executive Carrie Cox said in the statement. "We believe Sun Pharma is well positioned to support Organon's businesses, employees and patients globally."Organon, which focuses on women's health, was formed in 2021 following its separation from pharmaceutical giant Merck (MRK).The deal, which requires approval from regulators and clearance from Organon's shareholders, is expected to complete early next year."This transaction is a logical next step in strengthening Sun Pharma's global business," according to Sun Pharma Managing Director Kirti Ganorkar. "In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years."Sun Pharma intends to fund the acquisition through a combination of available cash resources and committed financing from banks. The Indian company anticipates the transaction to allow it to enter the biosimilar market.For the year ended Dec. 31, Organon reported revenue of $6.22 billion and adjusted earnings before interest, taxes, depreciation and amortization of $1.91 billion. In February, the company said it expected revenue of $6.2 billion for the current year, while five analysts polled by FactSet estimate $6.15 billion.
$OGN
International
Ifo: German Export Morale Inches Up in April
German exporters turned slightly optimistic in April, while the overall sector moved neither forward nor backward due to geopolitical uncertainty, the ifo Institute said Monday.The ifo export expectations indicator increased to 0.1 point in April, from -0.7 points in March, as positive expectations roughly offset negative ones.Across the board, the export outlook for the automotive industry, electronics sector, and furniture manufacturers declined but remained generally positive. Expectations for shipments of food and beverages increased "significantly," while energy-intensive businesses forecasted lower exports.
$^SXXP
Mining & Metals
Big Banc Split to Complete Class A Share Split
Big Banc Split (BNK.TO) intends to complete a stock split of its Class A shares, citing strong performance of the shares, the fund said late on Friday.Class A shareholders of record at the close of business on May 1 will receive 20 additional Class A shares for every 100 Class A shares held.At completion of the share split, the Class A shares are expected to begin trading on an ex-split basis at the opening of trading on May 4.The preferred shares of the fund will not be affected and are expected to have downside protection from a decline in the value of the fund's portfolio of about 60%.Class A unitholders will continue to receive regular monthly non-cumulative cash distributions initially in the amount of $0.12 per Class A share, or $1.44 per year, following the Share Split. As a result, the total dollar amount of distributions to be paid to the holders of Class A shares is expected to increase by about 20%.The share split is subject to the approval of the Toronto Stock Exchange.
$BNK.TO